Amendments for: 033-2020-2021-Q3-815733

Agreement Value: $169,872,474.00
Agreement: Medicago Proposal to fill Canada's pandemic preparedness gap (815733). Mar 28, 2020 - Mar 31, 2024
Description:

The Project is in direct response to the global fight against COVID-19. The Project will be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.

Organization: Innovation, Science and Economic Development Canada
Recipient: Medicago inc. (For-profit organization)
Location: Quebec, Quebec, CA G1V3V9
Type: Contribution
Recipient's Operating Name: Medicago inc.
Federal Riding Name: Louis-Hébert (24044)
Program Name: SIF Stream3- Attraction

-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.

NAICS Code: 541710

Agreement Value: $169,872,474.00
Agreement: Medicago Proposal to fill Canada's pandemic preparedness gap
Organization: Innovation, Science and Economic Development Canada
Recipient: -
Type: -

Agreement Value: $200,000,000.00
Expected Results:

The direct and immediate benefit of the project's first stage is the rapid development of a plant-based vaccine that may lead to an effective vaccine for COVID-19. The second stage, building a GMP facility that can manufacture vaccine and antibodies, is expected to increase biomanufacturing capabilities and build on areas of strength and technological advantage to advance Canada's life sciences industry. This project anticipates to maintain 275 full-time jobs and to create 75 full-time jobs within Canada.

Organization: Innovation, Science and Economic Development Canada
Recipient: -
Type: -
Additional Information:

The amendment has been completed to increase the contribution amount from $173M to $200M. This is a partially repayable contribution.

Agreement Value: $173,000,000.00
Agreement: Medicago Inc. COVID-19 (815733). Mar 28, 2020 - Mar 31, 2024
Description:

The Project is in direct response to the global fight against COVID-19. The Project will be undertaken in two stages to (1) develop a plant-derived virus-like particle (VLP) vaccine for the prevention of COVID-19; and (2) establish a large-scale GMP Facility for vaccine and antibody production in Canada.

Expected Results:

The direct and immediate benefit of the project's first stage is the rapid development of a plant-based vaccine that may lead to an effective vaccine for COVID-19, and thus, help prevent the spread. The second stage, building a GMP facility that can manufacture vaccine and antibodies, is expected to increase biomanufacturing capabilities and build on areas of strength and technological advantage to advance Canada's life science's industry.

Organization: Innovation, Science and Economic Development Canada
Recipient: Medicago inc. (For-profit organization)
Location: Quebec, Quebec, CA G1V3V9
Type: Contribution
Additional Information:

This is a repayable contribution.

Recipient's Operating Name: Medicago inc.
Federal Riding Name: Louis-Hébert (24044)
Program Name: SIF Stream3- Attraction

-Encourage R&D that will accelerate technology transfer and commercialization of innovative products, processes and services;-Facilitate the growth and expansion of firms in Canada;-Attract and retain large scale investments to Canada; and-Advance industrial research, development and technology demonstration through collaboration between academia, non-profit organizations and the private sector.

NAICS Code: 541710